proudly_canadian.png

Greater than the sum of its parts1

Together

The first dual-drug advanced   
liposomal formulation2

PrVYXEOS® (daunorubicin and cytarabine liposome for injection) is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).3

red_hug.png

Longer

Superior overall survival in  
patients with high-risk AML1,3*

Median overall survival: 9.6 months with   
VYXEOS vs 6 months with conventional chemotherapy†

HR: 0.69, 95% CI: 0.52 – 0.90, p = 0.005 (2-sided)  
Events reported in 104/153 patients with VYXEOS vs 132/156.1,3‡

For patients >60 years old with AML, the NCCN Guidelines® recommend selecting a treatment option based on patient performance status, comorbid conditions, and adverse features such as subtype rather than chronologic age alone.4

VYXEOS

Designed for optimal synergistic activity

Discover VYXEOS
home_page_hr.png
made_in_canada_purple.png

The story of VYXEOS

Learn more
circle_image.png

*High-risk AML defined as t-AML or AML-MRC.

†Conventional chemotherapy includes the 7+3/5+2 regimen for induction and consolidation, using cytarabine and daunorubicin.2

‡Number of deaths reported from the Intent-to-Treat (ITT) population with VYXEOS (n = 153) vs the conventional chemotherapy arm (n = 156) from the phase 3, randomized, multicentre,open-label study evaluating the efficacy and safety of VYXEOS in adults with newly diagnosed high-risk sAML.2,3

References: 1. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692. 2. Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex® development platform. Future Oncol 2018;14:1317–1332. 3. Current VYXEOS® Product Monograph, Jazz Pharmaceuticals Canada, Inc. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

CA-VYX-2400004-E | March 2024